How do you differentiate between pre-existing and treatment-induced anti-AAV antibodies?

We establish a pre-treatment baseline for each subject to screen for pre-existing neutralizing antibodies (NAbs) and total binding antibodies (TAb) against the specific AAV serotype. Post-administration samples are then collected at multiple time points and compared against this baseline. A significant increase in titer, typically defined as a four-fold or greater rise, indicates a treatment-induced humoral response. This longitudinal analysis is fundamental for interpreting safety and efficacy data.

What is the standard approach for assessing T-cell responses to the AAV capsid and transgene product?

The standard approach involves functional assays using peripheral blood mononuclear cells (PBMCs). We utilize Enzyme-Linked Immunospot (ELISpot) assays to quantify the frequency of cytokine-secreting T cells (e.g., IFN-γ) in response to peptide pools spanning the AAV capsid or the transgene protein. For more granular data, intracellular cytokine staining (ICS) followed by flow cytometry can identify the specific T-cell subsets (CD4+, CD8+) responding to the vector components.

How can immunogenicity data from preclinical models be translated to predict human clinical outcomes?

While no preclinical model perfectly recapitulates human immunity, data from nonhuman primate (NHP) studies provide the most relevant translational insights. We focus on identifying concordant immune response patterns and potential safety signals between species. The data informs the design of the clinical immunogenicity monitoring plan, helps establish initial risk assessments, and can guide the development of potential immune modulation strategies. The goal is not direct extrapolation but informed risk mitigation.

What are the regulatory expectations for an AAV immunogenicity assessment package supporting an IND?

Regulatory bodies expect a multi-tiered testing strategy that evaluates both humoral (TAb and NAb) and cellular (T-cell) immune responses. The plan must include validated, sensitive, and specific assays. It should detail pre-treatment screening for pre-existing immunity, a clear schedule for post-treatment sample collection, and a pre-defined statistical approach for data analysis. The package must connect immunogenicity findings to potential impacts on bioactivity, pharmacokinetics, and patient safety.

A comprehensive immunogenicity profile is a strategic tool for de-risking any successful AAV gene therapy program. Proactive characterization of both humoral and cellular immune responses to the vector capsid and transgene product directly informs patient selection, dose optimization, and the interpretation of safety and efficacy signals. This analysis forms the foundation for a successful IND submission, which we support within an 18-24 month timeline.

GxP-Compliant Assays for Preclinical Development

All immunogenicity assessments for IND-enabling studies are conducted within our GxP-compliant framework in our >100,000 sq ft facility. We develop and validate fit-for-purpose assays that meet stringent regulatory expectations, ensuring the data package is robust and reliable. This commitment to quality has been a factor in our team’s 100% IND success rate since 2019 (with the Franklin Biolabs brand itself launching in 2024). Our bioanalytical data is designed to directly support program milestones by facilitating rapid biomarker discovery and accelerating clinical validation.

In vivo models are indispensable for evaluating AAV immunogenicity. All studies are performed in AAALAC-accredited facilities and comply with USDA regulations.